CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Leuprolide acetatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00076440
NCT00076440Phase 2Completed
CompareCT.gov

Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study

Voyager Pharmaceutical Corporation·interventional·Posted Jan 26, 2004·Updated Dec 11, 2009

In Brief

A Phase 2 clinical trial evaluating Leuprolide acetate for Alzheimer Disease. Completed, across 13 sites.

Detailed Summary

ALADDIN is a research study to investigate the safety and effectiveness of leuprolide (a hormone drug) to improve the cognitive function and slow the progression of Alzheimer's disease (AD) in men 65 years and older with mild to moderate Alzheimer's disease who reside in the community.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 26, 2004
Enrollment StartDec 1, 2003
Primary CompletionMar 1, 2007
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 22.4 years ago

Interventions

Leuprolide acetatedrug